Indications for: Moxidectin
Onchocerciasis due to Onchocerca volvulus.
Limitations of Use:
Does not kill adult O. volvulus parasites; follow-up advised. Safety and efficacy of repeat administration not studied.
8mg (4 tabs) as a single dose.
<12yrs: not established.
Risk of cutaneous, ophthalmological and/or systemic reactions (Mazzotti reaction) esp. in those with higher microfilarial burden; treat appropriately. Serious encephalopathy may occur if co-infected with Loa loa; screen for loiasis in endemic areas prior to treatment. Possible severe edema and worsening onchodermatitis in those with hyper-reactive onchodermatitis. Severe renal impairment, ESRD. Pregnancy. Nursing mothers: not recommended (during and for 7 days after treatment).
Eosinophilia, pruritus, musculoskeletal pain, headache, lymphopenia, tachycardia, rash, abdominal pain, hypotension, pyrexia, leukocytosis, influenza-like illness, neutropenia, cough, lymph node pain, dizziness, diarrhea, hyponatremia, peripheral swelling.